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Introduction
Recent multi-center randomized clinical trials (i.e. MADIT, AVID, MUSST) have shown that
mortality can be effectively reduced in selected post-infarction patients at high risk for sudden
cardiac death by implantation of a cardioverter-defibrillator1,2,3. As the selection of high risk
patients is a crucial part of prophylaxis, risk stratification strategies are becoming increasingly
important.
The sensitivity, the specificity and, in particular, the positive predictive accuracy of currently
used risk stratifiers are only moderate10,11. We recently introduced Heart Rate Turbulence
(HRT) as a new powerful risk predictor in survivors of myocardial infarction4. HRT is
characterised by an early acceleration and a late deceleration of the sinus rhythm after a single
ventricular premature complex (VPC). The acceleration starts immediately after the VPC and
lasts for only a small number of RR intervals. Subsequent deceleration reaches a maximum
usually around the 10th cycle following a VPC. The absence of this phenomenon indicates a
significantly increased risk of subsequent mortality. HRT is independent of the presently
available stratifiers. In the MPIP population, HRT and left ventricular ejection fraction
(LVEF) were the only independent risk predictors4.
The goal of this analysis was to develop a statistical model for the prediction of the survival
probability of post-infarction patients with arrhythmia based on LVEF and HRT. For this
purpose we used the data from the MPIP-trial.
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Methods
Patient population
Of the 715 survivors of acute myocardial infarction enrolled in the MPIP study 4, 134 patients
were excluded from our analyses because of atrial fibrillation, no VPCs during Holter
monitoring, missing LVEF or because of technically insufficient or missing Holter recordings.
The remaining 581 patients were used in this study. Their clinical characteristics are shown in
Table 1. The patients were followed for a maximum of 2 years during which 77 of them died.
Table 1: The MPIP data set
Variable Mean (SD)
Number (%)
HRT                                           (1)
                                                    (2)
154 (26.5%)
73 (12.6%)
LVEF 46.29 (14.83)
Salvos observed (Y/N) 67 (11.5%)
Number of extra systolic beats
in the longest salvo
3.21 (2.25)
Couplets observed (Y/N) 168 (28.9%)
Mean heart rate 72.02 (11.51)
Heart rate variability index 27.48 (13.06)
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Assessment of the risk predictors
Holter recordings were performed in the second or third week after the index infarction.
Initially, the Holter tapes were processed at Columbia University, New York with a Laser
Holter 8000 System (Marquette Medical Systems, WI, USA). After visual inspection and
manual editing, computer files were generated listing RR interval duration (sampling
frequency 128 Hz) and QRS morphological classifications on a beat-to-beat basis. The
following Holter risk predictors were quantified:
(1) Salvos present,
(2) Number of extra systolic beats in the longest salvo,
(3) Couplets present,
(4) mean heart rate (defined as the mean of all sinus rhythm cycles in a Holter recording),
(5) HRV triangular index (using the previously published technology),
(6) HRT (using the previously published technology 4, 13).
(7) LVEF was assessed two weeks after infarction by radionuclide ventriculography 4, 12.
Previous analyses have shown that among the parameters described, only LVEF and HRT
have a statistically significant impact on survival. Therefore, all further analyses have focused
on those two parameters.
Statistical analyses
The endpoint of the study was total mortality. The identification of important prognostic
factors was performed by the proportional hazard model of Cox (Cox, 1972). Based on the
results of previous analyses, we included in the model only LVEF and HRT. These two
factors were the only ones statistically significant correlated with mortality (Schmidt et al.,
1999). Variable HRT was categorical with three levels (0 = turbulence onset and turbulence
slope normal, 1 = turbulence onset or turbulence slope normal, 2 = turbulence onset and
turbulence slope abnormal). LVEF was used as continuous variable.
Results of all survival analyses are presented in form of Kaplan-Meier curves as survival
curves based on the result of the Cox-model and as relative risks with corresponding 95%
confidence limits. A significance level of 0.05 was used for the analyses.
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Results
The influence of LVEF on the mortality rate is shown in figure 1. The median of LVEF (46)
was used to split the sample. The difference between the survival rates of the resulting groups
was statistically significant. Figure 2 shows the survival rates for the patients in each of the
three categories of HRT. The influence of HRT remained significant in both sub-samples
divided with respect to LVEF (see figure 3). Therefore, both parameters were included in a
multivariate analysis in order to get a prognostic score for identifying the high risk group.
Figure 1: Survival curves for high and low values of LVEF (mean of 46 is used for
cut point)
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Figure 2: Survival curves for the three levels of HRT
Figure 3: Survival curves for HRT within the two groups divided by LVEF
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LVEF is measured on a continuous scale. First we investigated the appropriate form of the
influence of LVEF on mortality. The usual assumption is a linear effect and there are several
ways to check it. Following a proposal of Royston (2000), the first step is to use smoothing
splines7, 8 .
Figure 4: Influence of LVEF on the relative risk analyzed by smoothing splines,
fractional polynomials, and under the linear assumption.
From figure 4 it can be seen, that the effect of LVEF is not linear. In order to describe the
influence of LVEF in a functional form, we applied a technique called fractional
polynomials9. Within that approach the set of possible functions is restricted to
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with ßi the unknown coefficients and the exponents pi are selected among a given set of values
({-2, - 1.5, - 1, - 0.5, 0.5, 1, 1.5, 2, 2.5, 3, ln x}). A great variety of associations can be
modeled with this set of functions.
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It turned out that the relationship in the whole sample can be described adequately using one
of the following functions:
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Both functions are presented in fig. 4 together with the usual linear form. The goodness of fit
using either function is much larger compared with the linear function (R = 59.655 for
1 / LVEF2, R = 48.114 for lnLVEF and R = 39.554 for LVEF). However, the transformation
lnLVEF performed a better fit in the subgroups with higher risk (HRT 	

used in the further analysis together with HRT as categorical variable. In the multivariate
analysis both variables turned out to be statistically significant (Table 2). The goodness of fit
statistics increased to R = 71.887.
Table 2: Results of the Cox-model (n = 581 patients, 77 deaths)
variable ß p-value RR = eß (95 % CI)
ln LVEF -1.57 < 0.0001 ⎯*
HRT = 1 0.373 0.186 1.45 (0.84 – 2.52)
HRT = 2 0.891 0.003 2.44 (1.34 – 4.43)
* There is no relative risk given for LVEF. The risk depends on the values of LVEF. E. g. the relative risk
for a patients with LVEF = 20 compared to those with LVEF = 30 is 1.89. LVEF = 30 compared with
LVEF = 40 gives a relative risk of 1.57.
The following prognostic score (PS) can be obtained based on the result of the Cox-model:
-1.57⋅ ln LVEF HRT = 0
PS = -1.57⋅ ln LVEF + 0.373 HRT = 1
-1.57⋅ ln LVEF + 0.891 HRT = 2
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Figure 5 shows the relationship between the prognostic score PS, LVEF and HRT. Higher
score is associated with a higher mortality rate. A prognostic score of about -4.5 can be
obtained for the following values:
LVEF = 17 for HRT = 0,
LVEF = 22 for HRT = 1 and
LVEF = 31 for HRT = 2.
Figure 5:         Comparison of the prognostic score PS with LVEF and HRT.
For certain values for the prognostic score the corresponding survival rates are given in figure
6. E. g. a prognostic score of -4.5 is associated with a mortality rate of 32 % after 2 years of
follow-up.
Figure 6: Survival curves for some values of the prognostic score
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Discrimination between high and low risk
The discrimination between high and low risk patients can be based on several factors, e. g.
the prognostic score, the mortality rate at 2 years, or the percentage of patients in the high risk
group with their average risk at 2 years.
Figure 7 shows all three of the above criteria. Using the value of -4.5 for the prognostic score
for dividing the patients into low and high risk, about 7% of the sample belong to the high risk
group (score > -4.5) and their average 2 year mortality rate is about 47%. The additional line
(P(2)) gives the lower boundary of the 2 years mortality rate in the high risk group (32% for a
score of   -4.5). The appropriate cutpoint can be defined in using one of these criteria.
Figure 7: Comparison of the percentage of patients with prognostic score greater than
or equal to the value given on the x-axis and corresponding mortality rate at
two years together with the average risk in the group.
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Comparison of LVEF and the pair LVEF and HRT.
In order to show the advantage of using LVEF together with HRT instead of LVEF alone we
used the percentage of patients in the high risk group for comparison. Table 3 gives the
corresponding cut-points for LVEF together with the number of deaths in the high risk group.
Table 3: Comparison of the prognostic scores based on LVEF alone or LVEF in
combination with HRT
LVEF alone LVEF + HRT
2 years
mortality-rate (%)
2 years
mortality-rate (%)
percentage
of patients
in the high
risk group
LVEF deaths/n
min average
prognostic
score
deaths/n
min average
5 % 24 14/33 21.9 37.8 -4.34 17/33 37.0 49.6
10 % 27 24/63 18.1 28.8 -4.80 25/60 25.8 41.0
15 % 29 29/88 16.4 25.4 -4.97 33/87 21.9 35.7
20 % 32 35/117 14.6 22.9 -5.19 37/117 18.0 31.5
25 % 35 39/145 13.4 21.1 -5.30 42/145 16.3 28.7
It can be seen that the combination of LVEF and HRT is able to identify more deaths among
the same number of patients than LVEF alone and the mortality rates are always higher. The
lower the number of patients in the high risk group, the grater the difference in the mortality
rates.
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Discussion
Previous analyses have shown that among all prognostic factors measured in the MPIP
patients, LVEF and HRT were the only significant and independent risk predictors. The goal
of this study was to develop a statistical model which combines the information of both risk
predictors.
The statistical model presented in this paper is based on the proportional hazard model of
Cox6. HRT was used as a categorical variable with three outcomes, LVEF was used as a
continuous variable. The model results in a risk score, which can be converted into an
estimate of the probability of death within a predefined follow-up period and/or a
corresponding survival curve. The estimates provided by the model fitted well to the actual
mortality figures.
The great advantage of the new model is the exact estimation of the individual mortality risk.
In other models, where risk predictors are used either alone or in combination, the average risk
of patient groups is estimated. In case of the risk score presented here, a cut-off point of -4.4
would optimally separate a low risk subgroup (estimated average two-year mortality 11.2%)
from a high risk subgroup (estimated average two-year mortality 48.1%) (Figure 8).
Figure 8: Estimated two-year mortality risk presented as continuous variable and
dichotomized variable.
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Risk score
Within the low risk group, the individual two-year mortality risk may be as low as 3.2% and
as high as 35.2%. Within the high risk group, e.g., the individual two-year mortality risk
varies between 35.3% and 82.6%. Moreover, patients with only slightly different risk scores
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around the cut-off point (e.g. -4.3 and -4.5) would be assigned to different risk groups. Due to
these problems, the risk of individual patients may be over- or underestimated. A higher
number of subgroups, e.g. three ore more, would alleviate these errors, but not eliminate.
The new risk score is a sharper tool than the presently available models. This should facilitate
the decision whether or not an individual patient needs further diagnostic and therapeutic
procedures, be it an electrophysiological study or the implantation of a cardioverter defi-
brillator. Another advantage of the statistical model presented is that other independent risk
predictors can easily added to the model. In the case, that new methods, such as baroreflex
sensitivity, T-wave alternans (or others) will proof to be independent risk predictors in a
multivariate Cox analysis, the model will be re-adjusted in consideration of the β coefficients
of the new risk predictors.
Limitations: None of the MPIP patients was treated by thrombolysis during the acute phase of
infarction. Only a minority received betablockers, ACE inhibitors, lipid lowering drugs or
ASS during follow-up. The baseline hazard Λ0(t) probably has to be adjusted when the model
is used in post-MI patients treated by thrombolysis or PTCA/Stenting during the acute phase
and with the above mentioned drugs during the chronic phase of the infarction.
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